THE FIRST RUSSIAN EXPERIENCE OF ADALIMUMAB TREATMENT IN PSORIATIC ARTHRITIS
https://doi.org/10.14412/1995-4484-2010-448
Abstract
Objective. To evaluated effect of adalimumab treatment on activity of arthritis, enthesitis, psoriasis and functional status in PsA patients (pts).
Subjects and methods. 18 pts with active PsA (12 female, 6 male), median age 43,1±10,2 years (yrs) (range 24-56), median duration of
psoriasis 16,7±9,6 yrs (range 4-33), median duration of PsA 9,2±6,7 yrs (range 1,5-23) received Adalimumab 40 mg subcutaneously
every other week (wk) for 12 wks in open-label study. Evaluations of treatment effects were conducted by the PSARC, ACR 20, 50 and 70,
LEI, PASI, BSA, HAQ and CRP at wks 4 and 12.
Results. The sings of activity of PsA at baseline were: DAS=4,8 (4,0; 5,45), LEI=4,25 (0,25; 8,05), PASI=10,5 (7,2; 12,1), BSA=1,75
(1; 2), HAQ=1,125 (0,875; 1,5), СRР=27,9 (11,4; 34,6). After 4 wks all parameters significantly improved: DAS=2,85 (2,1; 3,1),
LEI=1,86 (0; 3,97), PASI=6,4 (2,8; 8), BSA=0,75 (0,15; 1), HAQ=0,375 (0,125; 0,625), СRP=1,7 (1,4; 3,2) and were maintained
after 12 wks: DAS=1,6 (1,3; 2,03), LEI=0,38 (0; 0,89), PASI=1,1 (0,4; 2,2), BSA=0 (0; 0,9), HAQ=0,312 (0; 0,625), СRР=1,75 (0,7;
3,6); p<0,05. 100% pts achieved PSARC at the 4 and 12 wks 55,6; 11,1 and 27,8% PsA pts achieved ACR 20, 50 and 70 at 4 wks and
11,1; 33,3 and 55,6% at 12 wks respectively. Adalimumab was well tolerated throughout the study.
Conclusion. Adalimumab therapy significantly reduced the main clinical symptoms of PsA: arthritis, enthesitis, psoriasis. Additionally it
improved quality of life PsA patients and was well tolerated.
Subjects and methods. 18 pts with active PsA (12 female, 6 male), median age 43,1±10,2 years (yrs) (range 24-56), median duration of
psoriasis 16,7±9,6 yrs (range 4-33), median duration of PsA 9,2±6,7 yrs (range 1,5-23) received Adalimumab 40 mg subcutaneously
every other week (wk) for 12 wks in open-label study. Evaluations of treatment effects were conducted by the PSARC, ACR 20, 50 and 70,
LEI, PASI, BSA, HAQ and CRP at wks 4 and 12.
Results. The sings of activity of PsA at baseline were: DAS=4,8 (4,0; 5,45), LEI=4,25 (0,25; 8,05), PASI=10,5 (7,2; 12,1), BSA=1,75
(1; 2), HAQ=1,125 (0,875; 1,5), СRР=27,9 (11,4; 34,6). After 4 wks all parameters significantly improved: DAS=2,85 (2,1; 3,1),
LEI=1,86 (0; 3,97), PASI=6,4 (2,8; 8), BSA=0,75 (0,15; 1), HAQ=0,375 (0,125; 0,625), СRP=1,7 (1,4; 3,2) and were maintained
after 12 wks: DAS=1,6 (1,3; 2,03), LEI=0,38 (0; 0,89), PASI=1,1 (0,4; 2,2), BSA=0 (0; 0,9), HAQ=0,312 (0; 0,625), СRР=1,75 (0,7;
3,6); p<0,05. 100% pts achieved PSARC at the 4 and 12 wks 55,6; 11,1 and 27,8% PsA pts achieved ACR 20, 50 and 70 at 4 wks and
11,1; 33,3 and 55,6% at 12 wks respectively. Adalimumab was well tolerated throughout the study.
Conclusion. Adalimumab therapy significantly reduced the main clinical symptoms of PsA: arthritis, enthesitis, psoriasis. Additionally it
improved quality of life PsA patients and was well tolerated.
About the Authors
Elena Yurievna LoginovaT V Korotaeva
N V Klimova
E N Aleksandrova
L N Denisov
Sh F Erdes
References
1. <div><p>Gladman D.D. Natural history of psoriatic arthritis. Baillieres Clin Rheumatol 1994;8(2):379-94.</p><p>Gladman D.D., Farewell V.T., Wong K. et al. Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthr Rheum 1998;41(6):1103-10.</p><p>McHugh N., Balachrishnan C., Jones S. Progression of peripheral joint disease in PsA: a 5 year prospective study. J Rheumatol 2003;42:778-83.</p><p>Stafford L., Kane D., Murphy E. et al. Psoriasis predicts a poor short-term outcome in patients with spondyloarthropathy. Arthr Rheum 2001;45:485-93.</p><p>Коротаева Т.В., Насонов Е.Л. Стандарты терапии псориатического артрита. Науч-практич ревматол 2009;3:29-37.</p><p>Коротаева Т.В. Адалимумаб - новые возможности терапии псориатического артрита (ПсА). Клин фармакол тер 2007;16(1):78-80.</p><p>Mease P., Gladman D., Ritchlin C. et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis. Arthr Rheum 2005;52(10):3279-89.</p><p>McHugh N., van den Bosch F., Manger B. et al. Adalimumab (Humirar) Treatment is Effective in patients with Psoriatic Arthritis (PsA) in Day-to-Day Clinical Practice - Results from the STEREO Trial. 25th Ann. General Meeting of the British Society for Rheumatology (BSR), UK, Liverpool, 2008, abs. 259.</p><p>Taylor W., Gladman D., Helliwell P. et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthr Rheum 2006;54:2665-73.</p><p>Gladman D., Helliwell P., Mease P. еt al. Assessment of patients with psoriatic arthritis. Arthr Rheum 2004;50(1):24-35.</p><p>Healy P.J., Helliwell P. Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthr Rheum 2008;59(5):686-91.</p><p>Fredriksson T., Pettersson U. Severe psoriasis: oral therapy with a new retinoid. Dermatologica 1978;157:238-44.</p><p>Mease P., Antoni C., Gladman D. et al. Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis 2005;64(Suppl. 2):ii49-ii54.</p><p>Clegg D., Reda D., Mejias E. et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. Department of Veterans Affaris Cooperative Study. Arthr Rheum 1996;39:2013-20.</p><p>Mease P., Kivitz A., Burch F. et al. Improvement in disease activity in patients with psoriatic arthritis reсeiving etanercept (Enbrel): results of a phase 3 multicenter clinical trial. Arthr Rheum 2001;44(Suppl. 1):S90.</p><p>Fries J.F., Spitz P., Kraines R.G. et al. Measurement of patients outcome in arthritis. Arthr Rheum 1980;23:137-45.</p><p>Bruce B., Fries J.F. The Health Assessment Questionnaire (HAQ). Clin Exp Rheumatol 2005;23 (Suppl. 39):S14-S18.</p><p>Chaundhary U., Romano P., Mulcahy L.D. et al. Efficacy and safety of infliхimab monotherapy for plaque-type psoriasis: randomised trial. Lancet 2001;357:1842-7.</p><p>Markham T., Fearon U., Mullan R. et al. Anti-TNF alpha therapy in psoriasis: clinical and angiogenic responses. Br J Dermatol 2003;143(Suppl. 59):40.</p><p>Van der Heijde D., Kivitz A., Schiff M.H. et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis. Results of a multicenter, randomized, double- blind, placebo-controlled trial. Arthr Rheum 2006;54:2136-46.</p><p>Sieper J., Griep E.N., Zamani O. et al. Adalimumab therapy reduces peripheral arthritis and enthesitis in patients with active ankylosing spondylitis in the RHAPSODY study. Ann Rheum Dis 2008;67(Suppl. II):SAT0267.</p><p>Ritchlin C., Mease P., Perdok R. et al. Is adalimumab an efficacious treatment for enthesitis of the achilles tendon in patients with spondyloarthritis? Arthr Rheum 2009;60 (Suppl. 10):S669, abst. 1788.</p></div><br />
Review
For citations:
Loginova E.Yu., Korotaeva T.V., Klimova N.V., Aleksandrova E.N., Denisov L.N., Erdes Sh.F. THE FIRST RUSSIAN EXPERIENCE OF ADALIMUMAB TREATMENT IN PSORIATIC ARTHRITIS. Rheumatology Science and Practice. 2010;48(3):83-87. (In Russ.) https://doi.org/10.14412/1995-4484-2010-448
Views:
915
Email this article 